Evidence map›Paper›PMID 30088325›Full record

ArticleAngewandte Chemie (International ed. in English)2018

Bioinspired Artificial Nanodecoys for Hepatitis B Virus.

Xuan Liu, Lunzhi Yuan, Liang Zhang, Yalin Mu, Xiaoling Li, Chao Liu, Peng Lv, Yali Zhang, Tong Cheng, Quan Yuan and 3 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Angewandte Chemie (International ed. in English), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
4.5field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 61 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. A Genetically Engineered Biomimetic Nanodecoy for the Treatment of Liver Fibrosis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024
    Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Exosomes in cancer immunoediting and immunotherapy.Asian journal of pharmaceutical sciences · 2022
    Review
  14. Article
  15. Genetically Engineered Cellular Membrane Vesicles as Tailorable Shells for Therapeutics.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2021
    Article
  16. Article
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 2 countries.

Xuan LiuState Key Laboratory of Molecular Vaccinology and Molecular Diagnostics & Center for Molecular Imaging and Translational Medicine, School of Public Health, Xiamen University, 361102, China.
Lunzhi YuanState Key Laboratory of Molecular Vaccinology and Molecular Diagnostics & National Institute of Diagnostics and Vaccine Development in Infectious Disease, School of Public Health and School of Life Science, Xiamen University, 361102, China.
Liang ZhangState Key Laboratory of Molecular Vaccinology and Molecular Diagnostics & National Institute of Diagnostics and Vaccine Development in Infectious Disease, School of Public Health and School of Life Science, Xiamen University, 361102, China.
Yalin MuState Key Laboratory of Molecular Vaccinology and Molecular Diagnostics & Center for Molecular Imaging and Translational Medicine, School of Public Health, Xiamen University, 361102, China.
Xiaoling LiState Key Laboratory of Molecular Vaccinology and Molecular Diagnostics & National Institute of Diagnostics and Vaccine Development in Infectious Disease, School of Public Health and School of Life Science, Xiamen University, 361102, China.
Chao LiuState Key Laboratory of Molecular Vaccinology and Molecular Diagnostics & Center for Molecular Imaging and Translational Medicine, School of Public Health, Xiamen University, 361102, China.
Peng LvState Key Laboratory of Molecular Vaccinology and Molecular Diagnostics & Center for Molecular Imaging and Translational Medicine, School of Public Health, Xiamen University, 361102, China.
Yali ZhangState Key Laboratory of Molecular Vaccinology and Molecular Diagnostics & National Institute of Diagnostics and Vaccine Development in Infectious Disease, School of Public Health and School of Life Science, Xiamen University, 361102, China.
Tong ChengState Key Laboratory of Molecular Vaccinology and Molecular Diagnostics & National Institute of Diagnostics and Vaccine Development in Infectious Disease, School of Public Health and School of Life Science, Xiamen University, 361102, China.
Quan YuanState Key Laboratory of Molecular Vaccinology and Molecular Diagnostics & National Institute of Diagnostics and Vaccine Development in Infectious Disease, School of Public Health and School of Life Science, Xiamen University, 361102, China.
Ningshao XiaState Key Laboratory of Molecular Vaccinology and Molecular Diagnostics & National Institute of Diagnostics and Vaccine Development in Infectious Disease, School of Public Health and School of Life Science, Xiamen University, 361102, China.
Xiaoyuan ChenLaboratory of Molecular Imaging and Nanomedicine, National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institutes of Health (NIH), Bethesda, MD 20892, USA.
Gang LiuState Key Laboratory of Molecular Vaccinology and Molecular Diagnostics & Center for Molecular Imaging and Translational Medicine, School of Public Health, Xiamen University, 361102, China.ORCID 0000-0003-2613-7286
Xiamen University · CNNational Institutes of Health · US

Funding

Laboratory of Molecular Imaging and NanomedicineZIAEB000073 · NIBIB · NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING · PI CHEN, XIAOYUAN · 2010 to 2020
$32.8M
Intramural NIH HHS Z99 EB999999Intramural NIH HHS ZIA EB000073
6 · The paper itself

Abstract

A facile route is presented for fabricating a new class of nanomimics that overexpress hepatitis B virus (HBV) receptor by a natural biosynthetic procedure against HBV infection. A nine-transmembrane HBV-specific receptor, human sodium taurocholate co-transporting polypeptide (hNTCP), was engineered to naturally immobilize it onto the cellular surface and subsequently trigger the budding of hNTCP-anchoring membrane vesicles (hNTCP-MVs) that favor the HBV virion. hNTCP-MVs could rapidly block HBV infection in cell models. Furthermore, hNTCP-MVs treatment could effectively prevent viral infection, spreading, and replication in a human-liver-chimeric mouse model of HBV infection. Our findings demonstrate the receptor-mediated antiviral effect of hNTCP-MVs to trick HBV and offer novel opportunities for further development of antiviral strategies in nanomedicine.

Indexed as

AnimalsBiomimeticsCell MembraneHepatitis B virusHep G2 CellsHumansImmobilized ProteinsMiceMicroscopy, ConfocalModels, BiologicalNanomedicineNanostructuresOrganic Anion Transporters, Sodium-DependentRecombinant ProteinsSymportersVirus InternalizationImmobilized ProteinsOrganic Anion Transporters, Sodium-DependentRecombinant Proteinssodium-bile acid cotransporterSymportershepatitis Binfection inhibitionnanomedicinenanovesiclesreceptors

Identifiers

PMID30088325
PMCPMC6447037
OpenAlexW2886642335

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.